untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:28:58Z</responseDate>
<request identifier=oai:HAL:hal-01134468v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01134468v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:INSERM</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Biology of the immunomodulatory molecule HLA-G in human liver diseases.</title>
<creator>Amiot, Laurence</creator>
<creator>Vu, Nicolas</creator>
<creator>Samson, Michel</creator>
<contributor>CHU Pontchaillou [Rennes]</contributor>
<contributor>Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>This work was supported by University of Rennes1 and Institut National de la Santé et de la Recherche Médicale (Inserm). This work was supported by grants from Ligue Nationale Contre le Cancer (Comité d’Ille et Vilaine, Comité des Côtes d’Armor, Comité de Loire-Atlantique).</contributor>
<description>International audience</description>
<source>ISSN: 0168-8278</source>
<source>EISSN: 0168-8278</source>
<source>Journal of Hepatology</source>
<publisher>Elsevier</publisher>
<identifier>hal-01134468</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01134468</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01134468/document</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01134468/file/Biology%20of%20the%20immunomodulatory%20molecule%20HLA-G.pdf</identifier>
<source>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01134468</source>
<source>Journal of Hepatology, Elsevier, 2015, 62 (6), pp.1430-1437. 〈10.1016/j.jhep.2015.03.007〉</source>
<identifier>DOI : 10.1016/j.jhep.2015.03.007</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jhep.2015.03.007</relation>
<identifier>PUBMED : 25772038</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/25772038</relation>
<language>en</language>
<subject lang=en>Viral hepatitis</subject>
<subject lang=en>Liver failure</subject>
<subject lang=en>Transplantationl Hepatocellular carcinoma</subject>
<subject lang=en>HLA-G</subject>
<subject>[SDV] Life Sciences [q-bio]</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>The non-classical human leukocyte antigen-G, HLA-G, plays an important role in inducing tolerance, through its immunosuppressive effects on all types of immune cells. Immune tolerance is a key issue in the liver, both in liver homeostasis and in the response to liver injury or cancer. It would therefore appear likely that HLA-G plays an important role in liver diseases. Indeed, this molecule was recently shown to be produced by mast cells in the livers of patients infected with hepatitis C virus (HCV). Furthermore, the number of HLA-G-positive mast cells was significantly associated with fibrosis progression. The generation of immune tolerance is a role common to both HLA-G, as a molecule, and the liver, as an organ. This review provides a summary of the evidence implicating HLA-G in liver diseases. In the normal liver, HLA-G transcripts can be detected, but there is no HLA-G protein. However, HLA-G protein is detectable in the liver tissues and/or plasma of patients suffering from hepatocellular carcinoma, hepatitis B or C, or visceral leishmaniasis and in liver transplant recipients. The cells responsible for producing HLA-G differ between diseases. HLA-G expression is probably induced by microenvironmental factors, such as cytokines. The expression of HLA-G receptors, such as ILT2, ILT4, and KIRD2L4, on liver cells has yet to be investigated, but these receptors have been detected on all types of immune cells, and such cells are present in liver. The tolerogenic properties of HLA-G explain its deleterious effects in cancers and its beneficial effects in transplantation. Given the key role of HLA-G in immune tolerance, new therapeutic agents targeting HLA-G could be tested for the treatment of these diseases in the future.</description>
<date>2015-03-12</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
